GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyout
Phase 3negativecamlipixantNegative
AI Analysis
Summary
GSK is ending development of camlipixant for refractory chronic cough, representing a significant setback for its $2 billion acquisition of Bellus Health.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
GSK discontinued development of camlipixant in Phase 3
Importance:8/10
Sentiment:
-0.90
Phase 3 terminationacquisitiondrug development failurechronic cough
Read the original article
Published by Endpoints News on July 17, 2026 11:05 AM